Adeno-associated viruses (AAV) have emerged as the lead vector in clinical trials and form
the basis for several approved gene therapies for human diseases, mainly owing to their …

Adeno-associated virus (AAV)-based vectors are promising gene delivery vehicles for human
gene transfer. One significant obstacle to AAV-based gene therapy is the high prevalence …

Recently, the impact of small ubiquitin-related modifier 1 (SUMO-1) on the regulation and
preservation of sarcoplasmic reticulum calcium adenosine triphosphatase (SERCA2a) function …

The rapid development of CRISPR–Cas technologies brought a personalized and targeted
treatment of genetic disorders into closer reach. To render CRISPR-based therapies precise …

Vectors mediating strong, durable, and tissue-specific transgene expression are mandatory
for safe and effective gene therapy. In settings requiring systemic vector administration, the …

Cardiac gene therapy has emerged as a promising option to treat advanced heart failure (HF).
Advances in molecular biology and gene targeting approaches are offering further novel …

Chronic heart failure is one of the leading causes of morbidity and mortality in Western countries
and is a major financial burden to the health care system. Pharmacologic treatment and …

Aims Mammalian myocardium has a finite but limited capacity to regenerate. Experimentally
stimulating proliferation of cardiomyocytes with extracellular regeneration factors like …

Human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) assert a
great future for the cardiovascular diseases, both to study them and to explore therapies. …

Dilated cardiomyopathy is the second most common cause for heart failure with no cure
except a high-risk heart transplantation. Approximately 30% of patients harbor heritable …